Anavex Life Sciences Corp.

AVXL

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001314052

SEC filings (opens in a new tab)

No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.8M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Anavex Life Sciences Corp. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of AVXL: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	141	1	145	+5
Shares	26.8M	6.39M	27.0M	+6.54M (+32.0%)
Value	$113.3M	$27.0M	$153.2M	+$66.9M (+77.4%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (24)

Institutions that held Anavex Life Sciences Corp. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to AVXL in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	6,740,696	$38.3M	0.00%
Nwam LLC	910,476	$5.17M	0.32%
ExodusPoint Capital Management, LP	127,270	$723.0K	0.01%
Trexquant Investment LP	56,365	$320.2K	0.00%
American Century Companies Inc	55,866	$317.3K	0.00%
Envestnet Asset Management Inc	38,295	$217.5K	0.00%
Forum Financial Management, LP	35,140	$199.6K	0.00%
Acadian Asset Management LLC	29,616	$168.0K	0.00%
Wolverine Trading, LLC	24,565	$139.5K	0.00%
Intech Investment Management LLC	23,556	$133.8K	0.00%
Balentine LLC	20,200	$114.7K	0.00%
Alpine Global Management, LLC	18,356	$104.3K	0.03%
Atria Investments LLC	13,300	$75.5K	0.00%
PVG Asset Management Corp	13,005	$73.9K	0.30%
Raymond James Financial Services Advisors, Inc.	12,275	$69.7K	0.00%
Raymond James & Associates	11,631	$66.1K	0.00%
Marex Group plc	10,000	$56.8K	0.00%
HSBC Holdings PLC	10,045	$56.5K	0.00%
Simplex Trading, LLC	6,756	$38.0K	0.00%
Flaharty Asset Management, LLC	1,000	$5.68K	0.00%
Jamison Private Wealth Management, Inc.	700	$3.98K	0.00%
Sterling Capital Management LLC	190	$1.08K	0.00%
Capital Performance Advisors LLP	135	$767	0.00%
Focused Wealth Management, Inc	500	–	–

Sold out (19)

Institutions that held Anavex Life Sciences Corp. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of AVXL in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Y-Intercept (Hong Kong) Ltd	94,578	$399.1K
D. E. Shaw & Co., Inc.	58,355	$246.3K
Marshall Wace, LLP	39,351	$166.1K
Dynamic Technology Lab Private Ltd	29,294	$124.0K
EntryPoint Capital, LLC	28,154	$118.8K
Brevan Howard Capital Management LP	25,801	$108.9K
Balyasny Asset Management LLC	24,349	$102.8K
Los Angeles Capital Management LLC	22,077	$93.2K
Fiduciary Alliance LLC	19,275	$79.6K
Sheaff Brock Investment Advisors, LLC	15,250	$64.4K
CIBC World Markets Inc.	14,187	$60.0K
E Fund Management Co., Ltd.	13,623	$57.5K
Principal Financial Group Inc	11,408	$48.1K
Inceptionr LLC	10,971	$46.3K
Man Group plc	10,685	$45.1K
Kelly Financial Services LLC	4,000	$16.9K
Pacer Advisors, Inc.	1,276	$5.38K
Cypress Capital, LLC	700	$2.95K
Comerica Bank	112	$473

Not filed for Q3 2024 yet (1)

Institutions that held Anavex Life Sciences Corp. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AVXL in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	6,391,472	$27.0M